Top

Published in:

01-10-2013 | Research

Overexpression of Metastasis-Associated in Colon Cancer-1 Associated with Poor Prognosis in Patients with Esophageal Cancer

Authors: Mingchen Zhu, Yijun Xu, Xuelian Mao, Yanfang Gao, Lijia Shao, Feng Yan

Published in: Pathology & Oncology Research | Issue 4/2013

Abstract

Recent studies have shown that expression of metastasis-associated in colon cancer-1(MACC1) is observed in different types of cancer and plays an important role in tumor metastasis. However, the expression of MACC1 and its possible role in esophageal cancer remains unknown. In this study, we determined the expression of MACC1 in esophageal cancer by utilizing immunohistochemistry and analyzed the relationship between the expression and esophageal cancer prognosis. Immunohistochemistry results showed that 47 of 85 cancer lesions (55.2 %) were stained positive, and high expression of MACC1 was correlated with the node metastasis and TNM stage (P < 0.05). The Kaplan-Meier survival curve showed that patients with high MACC1 expression had significantly reduced overall 5-year survival rates (P = 0.004). Cox regression analysis revealed that high expression of MACC1 was associated with increased risk of death (hazard ratio [HR] =2.25) in patients with esophageal cancer. These findings suggested that high expression of MACC1 was correlated with progression and metastasis of esophageal cancer and might serve as a novel prognostic marker for patients with esophageal cancer.

Pisani P, Parkin DM, Bray F et al (1999) Erratum: estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer, 83, 18–29 (1999). Int J Cancer 83:870–873PubMedCrossRef

Enzinger PC, Mayer RJ (2003) Esophageal cancer. N Engl J Med 349:2241–2252PubMedCrossRef

Blanchard P, Quero L, Hennequin C (2009) Prognostic and predictive factors of oesophageal carcinoma. Bull Cancer 96:379–389PubMed

Lin YC, Wu MY, Li DR et al (2004) Prognostic and clinicopathological features of E-cadherin, alpha-catenin, beta-catenin, gamma-catenin and cyclin D1 expression in human esophageal squamous cell carcinoma. World J Gastroenterol 10:3235–3239PubMed

Michaylira CZ, Wong GS, Miller CG et al (2010) Periostin, a cell adhesion molecule, facilitates invasion in the tumor microenvironment and annotates a novel tumor-invasive signature in esophageal cancer. Cancer Res 70:5281–5292PubMedCrossRef

Kadowaki T, Shiozaki H, Inoue M et al (1994) E-cadherin and alpha-catenin expression in human esophageal cancer. Cancer Res 54:291–296PubMed

Chen M, Cai E, Huang J et al (2012) Prognostic value of vascular endothelial growth factor expression in patients with esophageal cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 21:1126–1134PubMedCrossRef

Stoker M, Gherardi E, Perryman M et al (1987) Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 327:239–242PubMedCrossRef

Lesko E, Majka M (2008) The biological role of HGF-MET axis in tumor growth and development of metastasis. Front Biosci 13:1271–1280PubMedCrossRef

10.

Horiguchi N, Takayama H, Toyoda M et al (2002) Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine. Oncogene 21:1791–1799PubMedCrossRef

11.

Zhang YW, Vande Woude GF (2003) HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem 88:408–417PubMedCrossRef

12.

Vande Woude GF, Jeffers M, Cortner J et al (1997) Met-HGF/SF: tumorigenesis, invasion and metastasis. CIBA Found Symp 212:119–130, discussion 130–2, 148–154PubMed

13.

Gumustekin M, Kargi A, Bulut G et al (2011) HGF/c-Met overexpressions, but not met mutation, correlates with progression of non-small cell lung cancer. Pathol Oncol Res 18:209–218PubMedCrossRef

14.

Toschi L, Janne PA (2008) Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer. Clin Cancer Res 14:5941–5946PubMedCrossRef

15.

Birchmeier C, Birchmeier W, Gherardi E et al (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915–925PubMedCrossRef

16.

Okano J, Shiota G, Matsumoto K et al (2003) Hepatocyte growth factor exerts a proliferative effect on oval cells through the PI3K/AKT signaling pathway. Biochem Biophys Res Commun 309:298–304PubMedCrossRef

17.

Ye M, Hu D, Tu L et al (2008) Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells. Investig Ophthalmol Vis Sci 49:497–504CrossRef

18.

Stein U, Walther W, Arlt F et al (2009) MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 15:59–67PubMedCrossRef

19.

Shirahata A, Sakata M, Kitamura Y et al (2010) MACC 1 as a marker for peritoneal-disseminated gastric carcinoma. Anticancer Res 30:3441–3444PubMed

20.

Chundong G, Uramoto H, Onitsuka T et al (2011) Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis. Anticancer Res 31:1141–1145PubMed

21.

Shirahata A, Fan W, Sakuraba K et al (2011) MACC 1 as a marker for vascular invasive hepatocellular carcinoma. Anticancer Res 31:777–780PubMed

22.

Lang AH, Geller-Rhomberg S, Winder T et al (2012) A common variant of the MACC1 gene is significantly associated with overall survival in colorectal cancer patients. BMC Cancer 12:20PubMedCrossRef

23.

Qiu J, Huang P, Liu Q et al (2011) Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J Transl Med 9:166PubMedCrossRef

24.

Steeg PS (2006) Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12:895–904PubMedCrossRef

25.

Gupta GP, Massague J (2006) Cancer metastasis: building a framework. Cell 127:679–695PubMedCrossRef

26.

Fidler IJ (2002) Critical determinants of metastasis. Semin Cancer Biol 12:89–96PubMedCrossRef

27.

Liang P, Pardee AB (1992) Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 257:967–971PubMedCrossRef

28.

Peschard P, Park M (2007) From Tpr-Met to Met, tumorigenesis and tubes. Oncogene 26:1276–1285PubMedCrossRef

Title: Overexpression of Metastasis-Associated in Colon Cancer-1 Associated with Poor Prognosis in Patients with Esophageal Cancer
Authors: Mingchen Zhu
Yijun Xu
Xuelian Mao
Yanfang Gao
Lijia Shao
Feng Yan
Publication date: 01-10-2013
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 4/2013
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-013-9638-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2013

HER2 in Gastric Cancer: An Immunohistochemical Study on Tissue Microarrays and the Coressponding Whole-Tissue Sections with a Supplemental Fish Study

Predictors of Locoregional Recurrence in T1-2N0 Tongue Cancer Patients

Alternatives for the Intensive Follow-Up After Curative Resection of Colorectal Cancer. Potential Novel Biomarkers for the Recommendations

MicroRNA-424-5p Suppresses the Expression of SOCS6 in Pancreatic Cancer

miR-135a/b Modulate Cisplatin Resistance of Human Lung Cancer Cell Line by Targeting MCL1

Klotho Acts as a Tumor Suppressor in Cancers

Keynote webinar | Spotlight on antibody–drug conjugates in cancer